Hyperion garners $40M in second VC round

South San Francisco-based Hyperion Therapeutics has pocketed $40 million from its second round of venture capital. Sofinnova Ventures led the round with equal commitments by Highland Capital Partners and NEA, all of Menlo Park, CA. WRF Capital of Seattle, WA also participated

"The funding will allow us to complete the licensing deal with Medicis Pharmaceutical Corporation, build out our management team, advance our clinical trials in Urea Cycle Disorders and Hepatic Encephalopathy and begin the U.S. promotion of the only two FDA-approved compounds for the treatment of UCD," says Hyperion CEO Chris Rivera.

- check out the release for more information

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.